MARKET

COEP

COEP

Coeptis Therapeutics Inc
NASDAQ
1.410
+0.015
+1.08%
After Hours: 1.480 +0.07 +4.96% 18:39 02/07 EST
OPEN
1.430
PREV CLOSE
1.395
HIGH
1.550
LOW
1.320
VOLUME
354.17K
TURNOVER
0
52 WEEK HIGH
21.42
52 WEEK LOW
1.030
MARKET CAP
27.52M
P/E (TTM)
11.97
1D
5D
1M
3M
1Y
5Y
BRIEF-Coeptis Therapeutics And ShareIntel Enter Shareholder Service Agreement To Target Illegal Short Selling
Reuters · 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 1d ago
Coeptis Therapeutics Partners With University of Pittsburgh to Advance Cell Therapy Development in Oncology
Coeptis Therapeutics Partners With University of Pittsburgh to Advance Cell Therapy Development in Oncology
MT Newswires · 01/31 11:50
Coeptis Therapeutics Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From NASDAQ
Benzinga · 12/29/2022 20:38
Coeptis Therapeutics Receives Non-Compliance Notice From Nasdaq
Coeptis Therapeutics Receives Non-Compliance Notice From Nasdaq
MT Newswires · 12/29/2022 16:26
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/19/2022 21:31
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
Benzinga · 12/19/2022 11:13
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
Benzinga · 12/13/2022 15:01
More
About COEP
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing cell therapy platforms for cancer. The Company's product portfolio and rights are highlighted by a universal, multi-antigen chimeric antigen receptor (CAR)-T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Its CAR T therapies are revolutionizing the treatment of many blood cancers, including B cell leukemias and lymphomas by targeting specific proteins found in these cancers.

Webull offers kinds of Coeptis Therapeutics Holdings Inc stock information, including NASDAQ:COEP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COEP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COEP stock methods without spending real money on the virtual paper trading platform.